Home How to manage BRCA mutation carriers?
Article
Licensed
Unlicensed Requires Authentication

How to manage BRCA mutation carriers?

  • Laura Sabiani EMAIL logo , Julien Barrou , Jérome Mathis , Francois Eisinger , Marie Bannier , Eric Lambaudie and Gilles Houvenaeghel
Published/Copyright: May 27, 2020
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Hormone Molecular Biology and Clinical Investigation
From the journal Hormone Molecular Biology and Clinical Investigation Volume 41 Issue 3

Abstract

Inherited mutations in BRCA1 and BRCA2 genes increase the risk of development of cancer in organs especially in breast and ovary. Prevention and screening in BRCA mutation carriers are of high importance. Prophylactic surgeries are possible but are still insufficiently performed because they require surgical procedures in healthy patients. Guidelines for the management of BRCA mutations carriers must absolutely be part of the standard practice of all those involved in the management of these patients to increase the impact of the implementation of these preventive measures. There is no screening recommended for ovarian cancer. A risk-reducing bilateral salpingo-oophorectomy should be performed from age 35 to 40 years for BRCA1 mutation carriers and 40 to 45 years for BRCA2 mutation carriers. A screening for breast cancer should be performed annually from 30 years old by breast MRI and mammography. A risk-reducing bilateral mastectomy is recommended with nipple sparing mastectomy and immediate breast reconstruction from 30 years and before 40 years. A multidisciplinary care must be implemented for these patients with an important psychological support.

Keywords: breast cancer; BRCA mutation; ovarian cancer; prophylactic mastectomy; risk reducing surgery
Corresponding author: Dr. Laura Sabiani, M.D., Department of Surgical Oncology, Institut Paoli-Calmettes, 232, Boulevard Sainte Marguerite, 13009, Marseille, France. Phone: +33 4 91 22 33 33, E-mail:

  1. Research Funding: None declared.

  2. Conflict of interest: The authors have no conflict of interest to declare.

  3. Informed Consent: Not applicable.

  4. Ethical Approval: Not applicable.

References

1. PubMed – NCBI. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. USA: PubMed – NCBI. Available from: https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30207593 [Internet]. [cited 2019 Oct 9].Search in Google Scholar

2. Lynch HT, Silva E, Snyder C, Lynch JF. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J 2008;14:3–13. https://doi.org/10.1111/j.1524-4741.2007.00515.x.10.1111/j.1524-4741.2007.00515.xSearch in Google Scholar PubMed

3. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA 2019;322:652–65. https://doi.org/10.1001/jama.2019.10987.10.1001/jama.2019.10987Search in Google Scholar PubMed

4. Paul A, Paul S. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci Landmark Ed 2014;19:605–18. https://doi.org/10.2741/4230.10.2741/4230Search in Google Scholar PubMed PubMed Central

5. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–6. https://doi.org/10.1126/science.1088759.10.1126/science.1088759Search in Google Scholar PubMed

6. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269–75. https://doi.org/10.1002/cncr.29041.10.1002/cncr.29041Search in Google Scholar PubMed PubMed Central

7. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30. https://doi.org/10.1086/375033.Search in Google Scholar

8. van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010;124:643–51. https://doi.org/10.1007/s10549-010-0805-3.10.1007/s10549-010-0805-3Search in Google Scholar PubMed

9. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol Off J Am Soc Clin Oncol 2007;25:1329–33. https://doi.org/10.1200/JCO.2006.09.1066.10.1200/JCO.2006.09.1066Search in Google Scholar PubMed PubMed Central

10. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402–16. https://doi.org/10.1001/jama.2017.7112.10.1001/jama.2017.7112Search in Google Scholar PubMed

11. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 2007;44:467–71. https://doi.org/10.1136/jmg.2006.048173.10.1136/jmg.2006.048173Search in Google Scholar PubMed PubMed Central

12. Evans DGR, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. J Med Genet 2010;47:710–1. https://doi.org/10.1136/jmg.2009.075176.10.1136/jmg.2009.075176Search in Google Scholar

13. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811–4. https://doi.org/10.1093/jnci/djm203.10.1093/jnci/djm203Search in Google Scholar

14. Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia?. Lancet Lond Engl 1971;2:163. https://doi.org/10.1016/s0140-6736(71)92335-x.10.1016/S0140-6736(71)92335-XSearch in Google Scholar

15. Murdoch WJ, Van Kirk EA, Alexander BM. DNA damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med Maywood NJ 2005;230:429–33. https://doi.org/10.1177/15353702-0323006-11.10.1177/15353702-0323006-11Search in Google Scholar PubMed

16. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:4188–98. https://doi.org/10.1200/JCO.2013.48.9021.10.1200/JCO.2013.48.9021Search in Google Scholar PubMed

17. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 2008;27:1–9. https://doi.org/10.1097/pgp.0b013e31814b191f.10.1097/pgp.0b013e31814b191fSearch in Google Scholar PubMed

18. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230–6. https://doi.org/10.1097/01.pas.0000180854.28831.77.10.1097/01.pas.0000180854.28831.77Search in Google Scholar PubMed

19. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161–9. https://doi.org/10.1097/01.pas.0000213335.40358.47.10.1097/01.pas.0000213335.40358.47Search in Google Scholar PubMed

20. Poon C, Hyde S, Grant P, Newman M, Ireland Jenkin K. Incidence and characteristics of unsuspected neoplasia discovered in high-risk women undergoing risk reductive bilateral salpingooophorectomy. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2016;26:1415–20. https://doi.org/10.1097/IGC.0000000000000791.10.1097/IGC.0000000000000791Search in Google Scholar PubMed

21. Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, et al. Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series. Anticancer Res 2017;37:5241–8. https://doi.org/10.21873/anticanres.11948.10.21873/anticanres.11948Search in Google Scholar PubMed

22. Hermsen BBJ, Olivier RI, Verheijen RHM, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96:1335–42. https://doi.org/10.1038/sj.bjc.6603725.10.1038/sj.bjc.6603725Search in Google Scholar

23. L'Institut National du Cancer (INCa). Femmes porteuses d'une mutation de BRCA1 ou BRCA2 /Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque, Collection recommandations et référentiels. France: INCa, 2017 avril.Search in Google Scholar

24. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Cancer Netw JNCCN 2017;15:9–20. https://doi.org/10.6004/jnccn.2017.0003.10.6004/jnccn.2017.0003Search in Google Scholar

25. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–7. https://doi.org/10.1093/jnci/djn442.10.1093/jnci/djn442Search in Google Scholar

26. Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. In: Cochrane gynaecological, Neuro-oncology and orphan cancer group, editors. Cochrane database systematic reviews; 2018. Available from: http://doi.wiley.com/10.1002/14651858.CD012464.pub2 [Internet] [cited 2019 Oct 31].10.1002/14651858.CD012464.pub2Search in Google Scholar

27. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967–75. https://doi.org/10.1001/jama.2010.1237.10.1001/jama.2010.1237Search in Google Scholar

28. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97:457–67. https://doi.org/10.1016/j.ygyno.2005.01.039.10.1016/j.ygyno.2005.01.039Search in Google Scholar

29. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–15. https://doi.org/10.1056/NEJMoa020119.10.1097/00006254-200209000-00016Search in Google Scholar

30. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–22. https://doi.org/10.1056/NEJMoa012158.10.1016/S0959-8049(02)00269-1Search in Google Scholar

31. Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150. https://doi.org/10.1186/s12905-014-0150-5.10.1186/s12905-014-0150-5Search in Google Scholar PubMed PubMed Central

32. Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 2013;130:127–31. https://doi.org/10.1016/j.ygyno.2013.03.027.10.1016/j.ygyno.2013.03.027Search in Google Scholar PubMed

33. Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016;2:1434–40. https://doi.org/10.1001/jamaoncol.2016.1820.10.1001/jamaoncol.2016.1820Search in Google Scholar PubMed PubMed Central

34. Powell CB. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later. Gynecol Oncol 2014;132:261–3. https://doi.org/10.1016/j.ygyno.2014.01.018.10.1016/j.ygyno.2014.01.018Search in Google Scholar PubMed

35. Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, et al. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 2011;17:210–2. https://doi.org/10.1111/j.1524-4741.2010.01055.x.10.1111/j.1524-4741.2010.01055.xSearch in Google Scholar PubMed

36. Blok F, Roes EM, van Leenders GJLH, van Beekhuizen HJ. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review. BMC Cancer 2016;16:18. https://doi.org/10.1186/s12885-015-2011-5.10.1186/s12885-015-2011-5Search in Google Scholar PubMed PubMed Central

37. Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol 2011;121:472–6. https://doi.org/10.1016/j.ygyno.2011.02.012.10.1016/j.ygyno.2011.02.012Search in Google Scholar PubMed

38. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260–5. https://doi.org/10.1001/jama.283.17.2260.10.1001/jama.283.17.2260Search in Google Scholar PubMed

39. Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 2018;150:85–91. https://doi.org/10.1016/j.ygyno.2018.05.011.10.1016/j.ygyno.2018.05.011Search in Google Scholar PubMed

40. Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358–65. https://doi.org/10.1093/jnci/94.18.1358.10.1093/jnci/94.18.1358Search in Google Scholar PubMed

41. Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric J Int Menopause Soc 2016;19:419–22. https://doi.org/10.1080/13697137.2016.1209396.10.1080/13697137.2016.1209396Search in Google Scholar PubMed

42. Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 2016;155:365–73. https://doi.org/10.1007/s10549-016-3685-3.10.1007/s10549-016-3685-3Search in Google Scholar PubMed

43. Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 2016;374:454–68. https://doi.org/10.1056/NEJMra1503523.10.1056/NEJMra1503523Search in Google Scholar PubMed

44. Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, et al. German consortium for hereditary breast and ovarian cancer (GC-HBOC). High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 2019;175:217–28. https://doi.org/10.1007/s10549-019-05152-9.10.1007/s10549-019-05152-9Search in Google Scholar PubMed

45. Telli ML, Gradishar WJ, Ward JH. NCCN guidelines updates: breast cancer. J Natl Compr Cancer Netw JNCCN 2019;17:552–5. https://doi.org/10.6004/jnccn.2019.5006.Search in Google Scholar

46. Milne RL, Osorio A, Cajal TRY, Vega A, Llort G, de la Hoya M, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res Off J Am Assoc Cancer Res 2008;14:2861–9. https://doi.org/10.1158/1078-0432.CCR-07-4436.10.1158/1078-0432.CCR-07-4436Search in Google Scholar PubMed

47. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol Off J Am Soc Clin Oncol 2006;24:863–71. https://doi.org/10.1200/JCO.2005.03.6772.10.1200/JCO.2005.03.6772Search in Google Scholar PubMed PubMed Central

48. Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI-M, Collée M, Meijers-Heijboer HEJ, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2019;177:723–33. https://doi.org/10.1007/s10549-019-05345-2.10.1007/s10549-019-05345-2Search in Google Scholar PubMed PubMed Central

49. De Felice F, Marchetti C, Musella A, Palaia I, Perniola G, Musio D, et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol 2015;22:2876–80. https://doi.org/10.1245/s10434-015-4532-1.10.1245/s10434-015-4532-1Search in Google Scholar PubMed

50. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol Off J Am Soc Clin Oncol 2004;22:1055–62. https://doi.org/10.1200/JCO.2004.04.188.10.1200/JCO.2004.04.188Search in Google Scholar PubMed

51. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159–64. https://doi.org/10.1056/NEJM200107193450301.10.1056/NEJM200107193450301Search in Google Scholar PubMed

52. Elder EE, Brandberg Y, Björklund T, Rylander R, Lagergren J, Jurell G, et al. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast Edinb Scotl 2005;14:201–8. https://doi.org/10.1016/j.breast.2004.10.008.10.1016/j.breast.2004.10.008Search in Google Scholar PubMed

53. Eltahir Y, Werners LLCH, Dreise MM, van Emmichoven IAZ, Jansen L, Werker PMN, et al. Quality-of-life outcomes between mastectomy alone and breast reconstruction: comparison of patient-reported BREAST-Q and other health-related quality-of-life measures. Plast Reconstr Surg 2013;132:201e–9e. https://doi.org/10.1097/PRS.0b013e31829586a7.10.1097/PRS.0b013e31829586a7Search in Google Scholar PubMed

54. Didier F, Radice D, Gandini S, Bedolis R, Rotmensz N, Maldifassi A, et al. Does nipple preservation in mastectomy improve satisfaction with cosmetic results, psychological adjustment, body image and sexuality?. Breast Cancer Res Treat 2009;118:623–33. https://doi.org/10.1007/s10549-008-0238-4.10.1007/s10549-008-0238-4Search in Google Scholar PubMed

55. Jakub JW, Peled AW, Gray RJ, Greenup RA, Kiluk JV, Sacchini V, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg 2018;153:123–9. https://doi.org/10.1001/jamasurg.2017.3422.10.1001/jamasurg.2017.3422Search in Google Scholar PubMed PubMed Central

56. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol Off J Eur Soc Med Oncol 2016;27(5 Suppl):v103–10. https://doi.org/10.1093/annonc/mdw327.10.1093/annonc/mdw327Search in Google Scholar PubMed

57. Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat 2006;98:285–94. https://doi.org/10.1007/s10549-006-9161-8.10.1007/s10549-006-9161-8Search in Google Scholar PubMed

58. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 2001;286:2251–6. https://doi.org/10.1001/jama.286.18.2251.10.1001/jama.286.18.2251Search in Google Scholar PubMed

59. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 2019;121:15–21. https://doi.org/10.1038/s41416-019-0446-1.10.1038/s41416-019-0446-1Search in Google Scholar PubMed PubMed Central

60. Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res 2019;11:2321–37. https://doi.org/10.2147/CMAR.S189627.10.2147/CMAR.S189627Search in Google Scholar PubMed PubMed Central

61. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, et al. Interim results from the impact study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76:831–42. https://doi.org/10.1016/j.eururo.2019.08.019.10.1016/j.eururo.2019.08.019Search in Google Scholar PubMed PubMed Central

Received: 2019-11-09
Accepted: 2020-03-31
Published Online: 2020-05-27

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Special Section: "Update in the management of ovarian cancer"; Guest Editors: René Druckmann and Adolf E. Schindler
  2. Editorial
  3. Preface to special issue: update in the management of ovarian cancer
  4. Original Article
  5. Ovarian cancer screening in the general population
  6. Review Articles
  7. Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes
  8. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update
  9. Genetic testing in ovarian cancer – clinical impact and current practices
  10. The place of secondary complete cytoreductive surgery in advanced ovarian cancer
  11. An update on preoperative assessment of the resectability of advanced ovarian cancer
  12. Impact of retroperitoneal lymph node dissection in ovarian cancer – time for paradigm shift?
  13. Minireviews
  14. Ultrasound screening of ovarian cancer
  15. How to manage BRCA mutation carriers?
  16. Regular Issue
  17. Original Articles
  18. Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate
  19. The effectiveness of military physical exercise on irisin concentrations and oxidative stress among male healthy volunteers
  20. Periodontal status and bone metabolism in women in reproductive and postmenopausal periods
  21. Modulatory effect of tropisetron in the liver of streptozotocin-induced diabetes in rats: biochemical and histological evidence
  22. Celecoxib versus mefenamic acid in the treatment of primary dysmenorrhea
  23. The predictive role of amylase and lipase levels on pancreas injury diagnosis in patients with blunt abdominal trauma
  24. Case Report
  25. Low hormone levels during an attack of systemic capillary leak syndrome normalizing after treatment
https://doi.org/10.1515/hmbci-2019-0065
Keywords for this article
breast cancer; BRCA mutation; ovarian cancer; prophylactic mastectomy; risk reducing surgery

Articles in the same Issue

  1. Special Section: "Update in the management of ovarian cancer"; Guest Editors: René Druckmann and Adolf E. Schindler
  2. Editorial
  3. Preface to special issue: update in the management of ovarian cancer
  4. Original Article
  5. Ovarian cancer screening in the general population
  6. Review Articles
  7. Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes
  8. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update
  9. Genetic testing in ovarian cancer – clinical impact and current practices
  10. The place of secondary complete cytoreductive surgery in advanced ovarian cancer
  11. An update on preoperative assessment of the resectability of advanced ovarian cancer
  12. Impact of retroperitoneal lymph node dissection in ovarian cancer – time for paradigm shift?
  13. Minireviews
  14. Ultrasound screening of ovarian cancer
  15. How to manage BRCA mutation carriers?
  16. Regular Issue
  17. Original Articles
  18. Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate
  19. The effectiveness of military physical exercise on irisin concentrations and oxidative stress among male healthy volunteers
  20. Periodontal status and bone metabolism in women in reproductive and postmenopausal periods
  21. Modulatory effect of tropisetron in the liver of streptozotocin-induced diabetes in rats: biochemical and histological evidence
  22. Celecoxib versus mefenamic acid in the treatment of primary dysmenorrhea
  23. The predictive role of amylase and lipase levels on pancreas injury diagnosis in patients with blunt abdominal trauma
  24. Case Report
  25. Low hormone levels during an attack of systemic capillary leak syndrome normalizing after treatment
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 18.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hmbci-2019-0065/pdf
Scroll to top button